Reach
Get to the tumor.
Programmable durability
for solid-tumor cell therapy.
Ready when patients need them.
Built to endure when tumors fight back.
The durability gap
In recurrent GBM, CAR-T can shrink tumors. Control often does not last.
Before CAR-T
After CAR-T
8 of 13 Radiographic regressions 1.9 months Median PFS
WHAT DURABLE CONTROL REQUIRES
A response is only the beginning.
Durable control depends on all three.
Recognize
See enough of the disease.
KiraGen's focus
Resist
Keep working when the tumor fights back.
Our approach to resistance
Noise cancellation for cell therapy.
We use multiplex gene editing to help CAR-T cells resist several suppressive routes at once.
The tumor keeps sending the signals. We change which ones the cell can hear.
Explore KiraGen
Backed by investors. Supported by disease foundations.
Investor backing
Disease foundation support
